Avenue Therapeutics, Inc. (OTC:ATXI)
| Market Cap | 1.48M-40.0% |
| Revenue (ttm) | 0-100.0% |
| Net Income | -2.78M+54.7% |
| EPS | -0.85-140.3% |
| Shares Out | 3.29M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 5,020 |
| Open | 0.38 |
| Previous Close | 0.38 |
| Day's Range | 0.38 - 0.45 |
| 52-Week Range | 0.15 - 0.97 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 12.00(+2572.61%) |
| Earnings Date | Nov 13, 2026 |
No insider has filed an open-market purchase or sale here in the last 90 days, so there is nothing to score yet.
About ATXI
Avenue Therapeutics, Inc. functions as a specialized pharmaceutical enterprise, primarily dedicated to innovating and bringing to market medical therapies tailored for critical and intensive care environments within hospitals. Their leading product candidate is intravenous Tramadol, a synthetic opioid with a dual mechanism of action, currently undergoing Phase III clinical trials for the management of severe pain experienced by patients after surgery. Established in 2015, the company's operations are based in New York, New York.
$ATXI stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in ATXI holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by ATXI's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
ATXI Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New ATXI patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to ATXI from public contracts
Source: USAspending.gov
ATXI Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from ATXI’s recent data — informational, not investment advice